TVGN רווח נקי למניה (EPS TTM) Tevogen Bio

Tevogen Bio Holdings is implementing a scalable T-cell platform, reducing development costs to grow free cash flow. The current trailing twelve-month earnings per share demonstrate business resilience amid market shifts, where the parameter value equals -5.84. The leadership's scientific potential is accelerating testing, while expected Phase II trials against viruses are becoming a key medium-term growth driver.
פילוחים אנליטיים של חברת Tevogen Bio Holdings, Inc. (TVGN)

This indicator reflects the actual earnings per share over a rolling year, allowing for an assessment of business efficiency regardless of issuance impact. By analyzing the 12-month EPS history, an investor can see the net financial result of Tevogen Bio Holdings (TVGN), which in the biopharmaceutical sector depends directly on demand stability and the resilience of raw material supply chains to sanction risks.